Neumora Therapeutics
NMRA
113 hedge funds and large institutions have $129M invested in Neumora Therapeutics in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 28 closing their positions.
375% more call options, than puts
Call options by funds: $9.52M | Put options by funds: $2M
61% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 23
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
1% less funds holding
Funds holding: 114 → 113 (-1)
1.11% less ownership
Funds ownership: 42.13% → 41.01% (-1.1%)
6% less capital invested
Capital invested by funds: $137M → $129M (-$8.04M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.9M |
| 2 |
O
OrbiMed
New York
|
+$4.07M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
+$3.81M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.89M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$9.95M |
| 2 |
Millennium Management
New York
|
-$4.28M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.95M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.65M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.6M |
NMRA Hedge Fund Activity: Q2 2026 in Review
113 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q2 2026, worth a combined $129M — down 5.9% from $137M a quarter earlier.
Fund positioning in NMRA was balanced in Q2 2026: 28 funds opened new positions, 28 closed out, 37 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $10.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.95M sold.
- 113 institutional investors held Neumora Therapeutics (NMRA) as of Q2 2026, down from 114 in Q1 2026.
- Funds reported $129M of Neumora Therapeutics stock for Q2 2026, down 5.9% quarter-over-quarter.
- 28 funds opened new Neumora Therapeutics positions in Q2 2026 and 28 closed out, a net change of 0 holders.
- The largest Neumora Therapeutics buyer in Q2 2026 was BlackRock, an estimated $10.9M added.
- The largest Neumora Therapeutics seller in Q2 2026 was Perceptive Advisors, an estimated $9.95M sold.
Based on aggregated 13F filings for Q2 2026.